Relative expression of matrix metalloproteinase-2 and -9 in synovial fluid from healthy calves and calves with experimentally induced septic arthritis

American Journal of Veterinary Research

Volumn 69, Issue 8, 2008, Pages 1022-1028

  Francoz, David ^a   Desrochers, André ^a   Simard, Nathalie ^b,e   Saint Pierre, Yves ^b   Fecteau, Gilles ^a   Latouche, Jean Sébastien ^a,c   Fortin, Mado ^a,d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INRS INSTITUT ARMAND FRAPPIER   (Canada)

^c Veterinary Diagnostic Imaging and Cytopathology   (United States)

^d Laboratoire d'Épidemiosurveillance Animale du Québec   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTIOFUR; GELATINASE A; GELATINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHROCENTESIS; ARTICLE; BACTERIAL ARTHRITIS; CALF (MAMMAL); CONTROLLED STUDY; ESCHERICHIA COLI; EXPERIMENTAL ANIMAL; JOINT IRRIGATION; LAVAGE; MALE; NEUTROPHIL COUNT; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SYNOVIAL FLUID; ZYMOGRAPHY;

ANIMALS; ARTHRITIS, INFECTIOUS; CATTLE; ESCHERICHIA COLI INFECTIONS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; REFERENCE VALUES; SYNOVIAL FLUID;

ANIMALIA; ESCHERICHIA COLI;

EID: 49749117444     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.8.1022     Document Type: Article

References (38)

1. Bertone AL. Infectious arthritis. In: McIlwraight CW, Trotter GW eds. Joint disease in the horse. Philadelphia: WB Saunders Co, 1996;397-409.
2. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
3. Cawston TE, Weaver L, Coughlan RJ, et al. Synovial fluids from infected joints contain active metalloproteinases and no inhibitory activity. Br J Rheumatol 1989;28:386-392.
4. Koolwijk P, Miltenburg AM, van Erck MG, et al. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 1995;22:385-393.
5. Coughlan AR, Robertson DH, Bennett D, et al. Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis. Vet Rec 1998;143:219-223.
6. Clegg PD, Coughlan AR, Riggs CM, et al. Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine Vet J 1997;29:343-348.
7. Arican M, Coughlan AR, Clegg PD, et al. Matrix metalloproteinases 2 and 9 activity in bovine synovial fluids. J Vet Med A Physiol Pathol Clin Med 2000;47:449-456.
8. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum 2002;46:13-20.
9. Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992;7:120-125.
10. Goldberg GI, Strongin A, Collier IE, et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992;267:4583-4591.
11. Woessner JF Jr. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann N Y Acad Sci 1999;878:388-403.
12. Francoz D, Desrochers A, Fecteau G, et al. Synovial fluid changes in induced infectious arthritis in calves. J Vet Intern Med 2005;19:336-343.
13. Francoz D, Desrochers A, Latouche JS. Effect of repeated arthrocentesis and single joint lavage on cytologic evaluation of synovial fluid in 5 young calves. Can J Vet Res 2007;71:129-134.
14. Esteve PO, Tremblay P, Houde M, et al. In vitro expression of MMP-2 and MMT-9 in glioma cells following exposure to inflammatory mediators. Biochim Biophys Acta 1998;1403:85-96.
15. Lakritz J, Marsh AE, Cockrell M, et al. Characterization of gelatinases in bronchoalveolar lavage fluid and gelatinases produced by alveolar macrophages isolated from healthy calves. Am J Vet Res 2004;65:163-172.
16. Simonen-Jokinen TL, Eskelinen UM, Härtel HM, et al. Gelatinolytic matrix metalloproteinases-2 and -9 in tracheobronchial lavage fluid obtained from calves with concurrent infections of Pasteurella multocida and Mycoplasma bovirhinis. Am J Vet Res 2005;66:2101-2106.
17. Clegg PD, Burke RM, Coughlan AR, et al. Characterisation of equine matrix metalloproteinase 2 and 9, and identification of the cellular sources of these enzymes in joints. Equine Vet J 1997;29:335-342.
18. Hibbs MS, Hasty KA, Seyer JM, et al. Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 1985;260:2493-2500.
19. Makowski GS, Ramsby ML. Zymographic analysis of latent and activated forms of matrix metalloproteinase-2 and -9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin Chim Acta 2003;329:77-81.
20. Lu KH, Yang SF, Chu SC, et al. The significance of altered gelatinase expression in the synovium of patient with arthritic effusions. Clin Rheumatol 2004;23:21-26.
21. Calander AM, Starckx S, Opdenakker G, et al. Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis. Microbes Infect 2006;8:1434-1439.
22. Jouglin M, Robert C, Valette JP et al. Metalloproteinases and tumor necrosis factor-alpha activities in synovial fluids of horses: correlation with articular cartilage alterations. Vet Res 2000;31:507-515.
23. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-160.
24. Xue M, March L, Sambrook PN, et al. Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activared protein C. Arthritis Rheum 2007;56:2864-2874.
25. Kouwenhoven M, Carlström C, Özenci V et al. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J Clin Immunol 2001;21:365-375.
26. Ries C, Loher F, Zang C, et al. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999;5:1115-1124.
27. Abraham M, Shapiro S, Lahat N, et al. The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol 2002;14:1449-1457.
28. Lee EO, Kang JL, Chong YH. The amyloid-β peptide suppress transforming growth factor-β1-induced matrix metalloproteinase-2 production via Smad7 expression in human monocytic THP-1 cells. J Biol Chem 2005;280:7845-7853.
29. Jansen PL, Kever M, Rosch R, et al. Polymeric meshes induce zonal regulation of matrix metalloproteinase-2 gene expression by macrophages and fibroblasts. FASEB J 2007;21:1047-1057.
30. Brama PA, van den Boom R, DeGroott J, et al. Collagenase-1 (MMP-1) activity in equine synovial fluid: influence of age, joint pathology, exercise and repeated arthrocentesis. Equine Vet J 2004;36:34-40.
31. Lohmander LS, Dahlberg L, Eyre D, et al. Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. Osteoarthritis Cartilage 1998;6:351-361.
32. van den Boom R, Brama PA, Kiers GH, et al. The influence of repeated arthrocentesis and exercise on matrix metalloproteinase and tumour necrosis factor alpha activities in normal equine joints. Equine Vet J 2004;36:155-159.
33. Manicourt DH, Fujimoto N, Obata K, et al. Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994;37:1774-1783.
34. Chambers MG, Cox L, Chong L, et al. Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum 2001;44:1455-1465.
35. Brama PA, TeKoppele JM, Beekman B, et al. Matrix metalloproteinase activity in equine synovial fluid: influence of age, osteoarthritis, and osteochondrosis. Ann Rheum Dis 1998;57:697-699.
36. Santavirta S, Takagi M, Konttinen YT, et al. inhibitory effect of cephalotin on matrix metalloproteinase activity around loose hip prostheses. Antimicrob Agents Chemother 1996;40:244-246.
37. Cainelli G, Galletti P, Garbisa S, et al. 4-alkylidene-azetidin-2-ones: novel inhibitors of leukocyte elastase and gelatinase. Bioorg Med Chem 2003;11:5391-5399.
38. Itoh T, Matsuda H, Tanioka M, et al. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002;169:2643-2647.